share_log

东亚药业(605177.SH):卢立康唑原料药获得韩国原料药品注册证书

Zhejiang East-Asia Pharmaceutical (605177.SH): Luliconazole Active Pharmaceutical Ingredient has obtained the Active Pharmaceutical Ingredient registration certificate from South Korea.

Gelonghui Finance ·  Jan 20 07:33

On January 20, Gelonghui reported that Zhejiang East-Asia Pharmaceutical (605177.SH) announced the receipt of the Active Pharmaceutical Ingredient registration certificate from the South Korea Ministry of Food and Drug Safety (South Korea MFDS) for Luliconazole, which is used to treat superficial fungal infections caused by sensitive fungi such as tinea pedis, tinea corporis, and tinea cruris. It can also be used for cutaneous candidiasis and tinea versicolor. The company's Luliconazole Active Pharmaceutical Ingredient has obtained the registration certificate in South Korea, marking the eligibility for entry into the South Korean market, which will positively impact the company's expansion into the South Korean pharmaceutical market and help promote the sales of Luliconazole Active Pharmaceutical Ingredient in other overseas markets.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Comment Comment · Views 322

Recommended

Write a comment

Statement

This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.